Breast cancer treatment is becoming more personalized, with doctors now choosing between intensifying therapy for aggressive cancers and scaling back treatment for patients with lower-risk disease. Major findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting show that the field is moving toward matching treatment intensity to each patient's actual risk level, guided by new biomarkers and drug combinations.

What's Changing in How Doctors Treat Breast Cancer?

The shift reflects two parallel strategies emerging from recent clinical trials. For patients with higher-risk or metastatic breast cancer, researchers are testing more aggressive or more targeted treatment approaches. Meanwhile, for early-stage hormone receptor-positive breast cancer, new genomic testing is helping many patients avoid chemotherapy altogether without compromising survival rates.

This represents a fundamental change in how oncologists think about breast cancer. Rather than using a one-size-fits-all approach, doctors are increasingly using tumor biology and genetic markers to determine who needs intensive treatment and who can safely receive less toxic options.

Which Patients Can Safely Skip Chemotherapy?

One of the most significant findings involves early-stage hormone receptor-positive, HER2-negative breast cancer. The OPTIMA trial enrolled 4,429 patients and used a genomic test called Prosigna PAM50 to measure the risk of cancer recurrence. The results were striking: in the test-directed treatment group, 68% of patients had low-risk scores and could avoid chemotherapy.

Among patients identified as low-risk through genomic testing, the 5-year invasive breast cancer-free survival rate was 93.7% with test-directed treatment compared to 94.9% in the control group that received standard chemotherapy. This small difference met the study's noninferiority threshold, meaning the genomic-guided approach was just as effective while sparing patients from chemotherapy's side effects.

How to Determine Your Personalized Breast Cancer Treatment Plan

• Biomarker Testing: Ask your oncologist about genomic tests like Prosigna PAM50 for early-stage hormone receptor-positive breast cancer. These tests measure your tumor's risk of recurrence and can guide whether chemotherapy is necessary.
• HER2 and PD-L1 Status: For triple-negative breast cancer, testing for HER2 expression and PD-L1 protein levels determines which targeted drugs you may be eligible for, including newer antibody-drug conjugates that may be more effective than traditional chemotherapy.
• BRCA and Tumor-Infiltrating Lymphocytes: Genetic testing for BRCA mutations and assessment of tumor-infiltrating lymphocytes (TILs), which measure how engaged your immune system is with the cancer, can help oncologists decide between chemotherapy, immunotherapy, or PARP inhibitors.
• Clinical Trial Eligibility: Discuss whether you qualify for clinical trials testing newer drug combinations or de-escalation strategies, as these may offer access to cutting-edge treatments tailored to your specific tumor characteristics.

What's New for Triple-Negative Breast Cancer?

Triple-negative breast cancer, which lacks hormone receptors and the HER2 protein, has historically been the most difficult type to treat. However, recent approvals and trial results are changing the landscape significantly.

For early-stage triple-negative breast cancer, the final analysis of the KEYNOTE-522 trial confirmed long-term benefits of combining pembrolizumab immunotherapy with chemotherapy before and after surgery. With 7 years of follow-up data, the combination improved event-free survival by 8.5 percentage points (78.3% versus 69.8%) and overall survival by 7.9 percentage points (85.1% versus 77.2%) compared to chemotherapy alone.

Importantly, researchers are also exploring ways to reduce chemotherapy intensity in early-stage triple-negative breast cancer. Studies are examining tumor-infiltrating lymphocytes (TILs) as a biomarker to identify which patients can safely avoid anthracycline chemotherapy, a class of potent drugs that can cause serious side effects. Tumors with TILs greater than 50% have over a 90% five-year recurrence-free survival rate without chemotherapy, suggesting that immune engagement alone may be sufficient for some patients.

How Are Newer Drugs Changing Metastatic Breast Cancer Treatment?

For metastatic breast cancer, antibody-drug conjugates (ADCs) are emerging as powerful new options. These drugs work by attaching chemotherapy directly to antibodies that target cancer cells, potentially delivering more potent treatment with fewer side effects on healthy tissue.

The ASCENT-03 trial tested sacituzumab govitecan, an ADC, against standard chemotherapy in patients with metastatic triple-negative breast cancer who were not candidates for immunotherapy. The biomarker analysis showed that the drug provided benefit across different levels of Trop-2 expression (a protein on cancer cells), tumor BRCA status, and HER2 expression subgroups. This finding was clinically important because it suggested the drug's effectiveness was not limited only to patients with the highest Trop-2 levels.

For HER2-positive metastatic breast cancer, the DESTINY-Breast09 trial compared trastuzumab deruxtecan, an ADC, plus pertuzumab against the standard first-line regimen of taxane chemotherapy, trastuzumab, and pertuzumab in 1,157 patients. The ADC combination achieved a median progression-free survival of 40.7 months compared to 26.9 months with standard therapy, representing a 44% reduction in the risk of progression or death.

Why Does Biomarker Testing Matter More Than Ever?

As newer, more targeted drugs move earlier in breast cancer treatment, accurate biomarker testing has become critical. The ASCENT-03 and DESTINY-Breast09 trials both highlighted how HER2 classification and other molecular markers directly affect which drugs patients can access and which are most likely to work.

Breast cancer treatment selection increasingly depends on reliable pathology, molecular testing, and careful interpretation of biomarker-defined subgroups. This means that getting the right tests done upfront, and having those results accurately interpreted, can significantly impact your treatment options and outcomes.

What Should Patients Do Now?

If you have been diagnosed with breast cancer or are at high risk, discuss with your oncologist whether you are a candidate for genomic testing to guide your treatment plan. For early-stage hormone receptor-positive breast cancer, ask specifically about tests like Prosigna PAM50 that may help you avoid chemotherapy. For triple-negative or HER2-positive breast cancer, ensure your tumor has been tested for relevant biomarkers including HER2 status, PD-L1 expression, and BRCA mutations.

Additionally, ask your care team about clinical trials, as many of the newer drug combinations discussed at ASCO 2026 are available through research studies. These trials often provide access to cutting-edge treatments and contribute to the growing body of evidence that is making breast cancer care more precise and more effective.